These invasive cancers are further classified based on molecular characteristics, such as hormone receptor status (HR-positive or HER2-positive) and triple-negative status (lacking expression of oestrogen, progesterone, and HER2 receptors), influencing treatment strategies and prognosis. The gene discussed is ERBB2; the disease is cancer.